Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis

Halle R Amick,1 Gerald Gartlehner,2,3 Bradley N Gaynes,4 Catherine Forneris,4 Gary N Asher,5 Laura C Morgan,2 Emmanuel Coker-Schwimmer,1 Erin Boland,2 Linda J Lux,2 Susan Gaylord,6 Carla Bann,2 Christiane Barbara Pierl,3 Kathleen N Lohr2

ABSTRACT

STUDY QUESTION
What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults?

METHODS
This was a systematic review including qualitative assessment and meta-analyses using random and fixed effects models. Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature were searched from January 1990 through January 2015. The 11 randomized controlled trials included compared a second generation antidepressant CBT. Ten trials compared antidepressant monotherapy with CBT alone; three compared antidepressant monotherapy with antidepressant plus CBT.

SUMMARY ANSWER AND LIMITATIONS
Meta-analyses found no statistically significant difference in effectiveness between second generation antidepressants and CBT for response (risk ratio 0.91, 0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change in 17 Item Hamilton Rating Scale for Depression score (weighted mean difference, −0.38, −2.87 to 2.10). Similarly, no significant differences were found in rates of overall study discontinuation (risk ratio 0.90, 0.49 to 1.65) or discontinuation attributable to lack of efficacy (0.40, 0.05 to 2.91). Although more patients treated with a second generation antidepressant than receiving CBT withdrew from studies because of adverse events, the difference was not statistically significant (risk ratio 3.29, 0.42 to 25.72). No conclusions could be drawn about other outcomes because of lack of evidence. Results should be interpreted cautiously given the low strength of evidence for most outcomes. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with CBT, and many of the included trials had methodological shortcomings that may limit confidence in some of the findings.

WHAT THIS STUDY ADDS
Second generation antidepressants and CBT have evidence bases of benefits and harms in major depressive disorder. Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT. It is clear that these drugs are not equal in effectiveness and that more research is needed to understand the clinical outcomes of these treatments. However, primary care physicians require high quality evidence of the comparative effectiveness of the available treatments to select and manage the best options for their patients.

WHAT THIS STUDY ADDS
The available evidence suggests no difference in treatment effects of second generation antidepressants and cognitive behavioral therapies, either alone or in combination, in major depressive disorder. Given that patients may have personal preferences for one first line treatment over the other, both treatments should be made accessible, either alone or in combination, to primary care patients with major depressive disorder.

WHAT IS ALREADY KNOWN ON THIS TOPIC
Second generation antidepressants and cognitive behavioral therapy have evidence bases of benefits and harms in major depressive disorder. However, primary care physicians require high quality evidence of the comparative effectiveness of the available treatments to select and manage the best options for their patients.

WHAT THIS STUDY ADDS
The available evidence suggests no difference in treatment effects of second generation antidepressants and cognitive behavioral therapies, either alone or in combination, in major depressive disorder. Given that patients may have personal preferences for one first line treatment over the other, both treatments should be made accessible, either alone or in combination, to primary care patients with major depressive disorder.
inhibitors, and other drugs with related mechanisms of action that target specific neurotransmitters. Although these drugs have different mechanisms of action, evidence suggests that no substantial differences in benefits exist among them as a class.7

Although drug therapy is the treatment most frequently offered to depressed primary care patients, data from studies of antidepressant drugs show that approximately 20% of patients do not fill their prescriptions. Moreover, even if they start a course of treatment, they may discontinue early before receiving an adequate course.8 One reason for lack of adherence to second generation antidepressants is the frequency and severity of side effects. More than 60% of patients have at least one adverse effect during treatment with a second generation antidepressant. Although most adverse effects are minor (for example, constipation, diarrhea, and dizziness), they frequently lead to discontinuation of treatment.9

Patients’ preferences for starting or switching treatment may also play a key role in acceptance and continuation of treatment for major depressive disorder. Some research suggests that patients might prefer treatment with psychotherapy over drugs.10-16 Reasons for preferring psychotherapy over drugs include concerns about side effects and perceived “addictiveness” of drugs.12,15-18 In addition, women and ethnic minorities may be more likely to prefer psychotherapies over drugs.12,13,19-20 Regardless of which treatment patients prefer, some evidence suggests that patients who receive their treatment of choice fare better than those whose treatment is incongruous with their preferences.11,21

In general, psychotherapeutic interventions aim to help patients to identify how past and present factors may contribute to their depression and to teach them how to deal effectively with them.22-25 Cognitive behavioral therapy is based on a combination of basic behavioral and cognitive principles. Briefly, it helps patients to understand and examine how their thoughts, moods, and behaviors interact in a way that can result in or worsen depression. Patients are taught how to replace dysfunctional thoughts and behaviors with more adaptive ones, which can reduce distress and improve mood.

Given the range of available treatments for patients with major depressive disorder, each with its own evidence base of benefits and harms, primary care physicians require high quality evidence of the comparative effectiveness of the available treatments to select and manage the best options for their patients. This paper focuses on the comparative benefits of second generation antidepressants and cognitive behavioral therapies as an initial treatment of a current episode of major depressive disorder in adults. Our results come from a larger comparative effectiveness review of benefits and harms of second generation antidepressants, psychotherapies (including psychotherapies other than cognitive behavioral therapy), complementary and alternative medicine treatments, and exercise interventions for major depressive disorder funded by the US Agency for Healthcare Research and Quality.26

Methods
Detailed methods are available in the full report.26 The full search strategy is available in web appendix A. In brief, we searched Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature for randomized and non-randomized controlled trials published from January 1990 through January 2015. For drugs, we searched for individual generic drug names and broader second generation antidepressant related terms; for cognitive behavioral therapy studies, we used the terms “psychotherapy,” “cognitive therapy,” and “cognitive behavioral therapy” in titles or abstracts. To detect unpublished studies, we searched ClinicalTrials.gov, the World Health Organization’s International Clinical Trials Registry Platform, Drugs@FDA, the European Medicines Agency, the National Institute of Mental Health website, the American Psychological Association website, Scopus, the Conference Proceedings Citation Index, and reference lists of pertinent reviews and included trials.

Table 1 contains the eligibility criteria that we applied to search results. Briefly, we included studies that compared a second generation antidepressant with cognitive behavioral therapy for the initial treatment of a current episode of major depressive disorder in adults. Cognitive behavioral therapy is the umbrella “class” with which we compared second generation antidepressants. However, we recognize the challenge in organizing and categorizing psychological interventions in systematic reviews. In an effort to enhance the consistency of categorization of psychotherapies in this

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>Adult (18 years or older) outpatients with major depressive disorder during initial treatment attempt for current episode</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Second generation antidepressants approved for treatment of major depressive disorder by the US Food and Drug Administration: bupropion, citalopram, desvenlafaxine, duloxetine, fluoxetine, escitalopram, fluvoxamine, levomilnacipran, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, venlafaxine, vilarodine, vortioxetine</td>
</tr>
<tr>
<td><strong>Cognitive behavioral therapies as classified by Cochrane Collaborative Depression, Anxiety and Neurosis Group’s framework27</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Benefits: response, remission, speed of response, speed of remission, relapse, quality of life, functional capacity, suicidal ideas or behaviors, hospital admission</td>
</tr>
<tr>
<td>Harms: overall adverse events, withdrawals because of adverse events, serious adverse events, specific adverse events (including hyponatremia, seizures, suicidal ideas or behaviors, hepatotoxicity, weight gain, gastrointestinal symptoms, sexual side effects), withdrawals because of specific adverse events</td>
<td></td>
</tr>
<tr>
<td><strong>Study designs</strong></td>
<td>Benefits: randomized controlled trials, systematic reviews, and meta-analyses</td>
</tr>
<tr>
<td>In addition for harms: non-randomized controlled trials, prospective controlled cohort studies, retrospective controlled studies, case-control studies, all with minimum sample size of 500 participants</td>
<td></td>
</tr>
</tbody>
</table>
We graded the strength of evidence on the basis of guidance established by the US Agency for Healthcare Research and Quality for the Evidence-based Practice Center program.27 This approach, which is based largely on the approach developed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, incorporates five domains: study limitations, consistency, directness, precision, and reporting bias. Grades (high, moderate, low, insufficient) reflect the confidence we had about the evidence for a specific outcome on the comparative benefits and harms of the interventions.

Evidence suggests that no substantial differences in benefits exist among the different types of second generation antidepressants; therefore, in all meta-analyses we compared second generation antidepressants as a class with cognitive behavioral therapies. When we did meta-analyses, we assessed statistical heterogeneity in effects between studies by calculating the $\chi^2$ statistic and Cochran's $q$. We used the $I^2$ statistic (the proportion of variation in study estimates attributable to heterogeneity) to estimate the magnitude of heterogeneity. We examined potential sources of heterogeneity by using sensitivity and subgroup analyses.

For all analyses, we used random effects and fixed effects models to estimate comparative effects. We used DerSimonian and Laird models for random effects analyses. For studies with attrition, we used a “worst case” assumption that non-completers failed to respond or remit. We used funnel plots to assess publication bias, but given the small number of studies in our meta-analyses, these tests have low sensitivity to detect publication bias. We used Comprehensive Meta-analysis, version 3.2 (Biostat; Englewood, NJ, USA) for all meta-analyses.

**Patient involvement**

A representative of the National (US) Board of Directors of the National Alliance on Mental Illness participated in the refinement of the research topic and the development of the preliminary research questions and review criteria. The research question and a draft version of the report were posted online for input from all members of the public, including patients and their advocates. Dissemination of results will include a translation of the results into short, easy to read summaries and tools that can be used by patients, caregivers, and others who use healthcare services.

**Results**

**Literature searches and evidence base**

Our searches for the full report identified 7813 citations, of which we included 11 primary randomized controlled trials (reported in 14 articles) that compared a second generation antidepressant with cognitive behavioral therapy and provided data relevant to this paper (fig 1).28-43 Those studies provided information on 1511 patients with major depressive disorder.

Two trials were conducted in primary care settings;38 39 the remainder took place in outpatient mental healthcare locations. Four trials took place solely in the
United States; 30 35 37 38 other countries included Canada, 33 36 42 England, 39 Germany, 60 Iran, 43 and Romania. 42

Generally, patients were aged between 18 and 65 years; most trials reported a mean age between 35 and 45 years. In all trials, most patients were female. One trial enrolled only women. 38 In the few trials that reported race or ethnicity, a quarter of patients were non-white. All trials reported mean baseline severity of depression of at least a moderate degree; most trials reported mean baseline scores on the 17 item Hamilton Rating Scale for Depression between 16 (moderate depression) and 23 (severe). The total daily dose of each second generation antidepressant drug was within the usual ranges prescribed for adults.

Table 2 describes the 11 included trials (14 publications) of a second generation antidepressant compared with cognitive behavioral therapy. Second generation antidepressants used in the trials were fluoxetine, 31 fluvoxamine, 39 paroxetine, 33 37 39 sertraline, 38 40 venlafaxine, 33 38 citalopram, 43 and escitalopram. 30 42 Because of the inherent heterogeneity in delivery of psychotherapies, even for those under the umbrella of cognitive behavioral therapy, we used the individual studies’ definitions of the cognitive therapies provided. Six trials used cognitive behavioral therapy, 30 33 36 38 40 42 four used the specific cognitive therapy modality, 32 35 37 43 and one each used problem solving therapy and rational emotive therapy modalities. 32 39 Trial counts exceed 11 because one trial had both cognitive therapy and rational emotive therapy arms. 39 All but one trial compared second generation antidepressant monotherapy with cognitive behavioral therapy alone; Lam and colleagues compared second generation antidepressant monotherapy with second generation antidepressant plus cognitive behavioral therapy. 42 Two trials included an additional comparison of second generation antidepressant monotherapy with a combination of second generation antidepressant and cognitive behavioral therapy; 39 43 Treatment duration ranged from eight weeks to one year; some trials also reported follow-up results once patients were no longer receiving active treatments.

We present our findings first by treatment comparison (monotherapy comparisons followed by combination therapy comparisons). Within each comparison, we present the benefits followed by the harms. Table 3 summarizes the findings and respective strength of evidence ratings for all comparisons and outcomes.

Second generation antidepressant versus cognitive behavioral therapy: monotherapy comparisons

We did random effects meta-analyses of trials rated as at low or medium risk of bias for remission, response, and change in 17 item Hamilton Rating Scale for Depression score. We also did sensitivity analyses for those outcomes including additional trials rated as at high risk of bias. 30 31 36

For remission, we included three trials (four comparisons) with a total of 432 patients. 32 35 39 We analyzed results measured between 12 and 16 weeks. The three trials defined remission on the basis of a 17 item Hamilton Rating Scale for Depression score of either less than 7 or less than or equal to 7. 35 36 One trial also required a score less than or equal to 10 on the Beck Depression Inventory for remission. 30 Patients treated with second generation antidepressants had numerically lower but not significantly different remission rates than patients receiving cognitive behavioral therapy (40.7% v 47.9%; risk ratio 0.98, 95% confidence interval 0.73 to 1.32; fig 2; low strength of evidence). Our sensitivity analysis including three trials at high risk of bias yielded a similar, non-significant difference (risk ratio 1.08, 0.90 to 1.29). 30 33 36

For response, we included results from 660 patients studied in five trials (six comparisons). 32 35 37 39 40 We analyzed results measured between eight and 16 weeks. The five trials defined response as a 50% or greater reduction from baseline in 17 item Hamilton Rating Scale for Depression score. Treatment effects were similar for second generation antidepressants and cognitive behavioral therapies (44.2% v 45.5%; risk ratio 0.91, 0.77 to 1.07; fig 3; moderate strength of evidence). The sensitivity analysis including three studies at high risk of bias yielded a similarly non-statistically significant difference in response between second generation antidepressants and cognitive behavioral therapies (risk ratio 1.02, 0.83 to 1.25). 30 31 36

Our analysis of the two trials (three comparisons; 249 patients) that reported change in 17 item Hamilton Rating Scale for Depression scores at eight weeks or longer found no statistically significant difference between second generation antidepressants and cognitive behavioral therapies (weighted mean difference −0.38, −2.87 to 2.10; fig 4). Adding the trials at high risk of bias to the model yielded no difference in comparative effectiveness (−0.27, −2.44 to 1.90). 33 40

Two trials, both rated as at medium risk of bias, reported response, remission, or change in 17 item Hamilton Rating Scale for Depression score at time points beyond 16 weeks. In one, 32 patients receiving either rational emotive therapy or cognitive therapy reported higher rates of remission and response at six months than patients taking a second generation antidepressant, although neither difference was statistically significant. At six months, patients receiving rational emotive therapy or cognitive therapy reported significantly lower 17 item Hamilton Rating Scale for Depression scores than did the patients taking the second generation antidepressant. In the trial that compared second generation antidepressants with problem solving therapy, 39 the rate of remission at one year was higher in the problem solving therapy arm, although rate of response at one year was higher in the second generation antidepressant arm. In that trial, patients’ 17 item Hamilton Rating Scale for Depression scores continued to decline, with one year scores being lower in the problem solving therapy arm than the second generation antidepressant arm. Again, these differences failed to reach statistical significance.

With respect to other health outcomes, three trials reported relapse rates during off treatment follow-up. 32 35 36 46 Two trials defined relapse as symptom...
Table 2 | Second generation antidepressants versus cognitive behavioral therapy: trial characteristics, main outcomes, and risk of bias ratings

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Sample size*; duration (weeks)</th>
<th>Total sample mean baseline severity (HRSD unless otherwise indicated)</th>
<th>Second generation antidepressant (dose, mg/day); psychotherapy subtype (No of sessions)</th>
<th>Response (%) and P value</th>
<th>Remission (%) and P value</th>
<th>Mean change in HRSD score from baseline and P value</th>
<th>Risk of bias rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>David et al, 2008; Sava et al, 2009</td>
<td>170; 14 treatment, 36 follow-up</td>
<td>22.5</td>
<td>Fluoxetine (40-80); cognitive therapy (20), rational emotive therapy (20)</td>
<td>At 14 weeks: v cognitive therapy: 58 v 63 (P&gt;0.05); v rational emotive therapy: 58 v 65 (P&gt;0.05)</td>
<td>Not reported</td>
<td>At 14 weeks: v cognitive therapy: 47 v 50 (P&gt;0.05); v rational emotive therapy: 47 v 44 (P&gt;0.05)</td>
<td>At 14 weeks: v cognitive therapy: −12.6 v −14.3 (P&gt;0.05); v rational emotive therapy: −12.6 v −14.3 (P&gt;0.05)</td>
</tr>
<tr>
<td>DeRubeis et al, 2005; Leykin et al, 2007; Landenberger, 2002</td>
<td>180; 84</td>
<td>23.4</td>
<td>Paroxetine (10-50); cognitive therapy (20-28)</td>
<td>50 v 43 (P=0.40)</td>
<td>Not reported</td>
<td>Effect size estimate: 0.16 (favors second generation antidepressant) (P=0.46)</td>
<td>Medium for response and remission; high for change in HRSD</td>
</tr>
<tr>
<td>Dimidjian, 2005</td>
<td>145; 16</td>
<td>20.7</td>
<td>Paroxetine (10-50); cognitive therapy (24)</td>
<td>43 v 58 (P=not reported)</td>
<td>27 v 42 (P=not reported)</td>
<td>Not reported</td>
<td>−6.5 v −8.8 (P=not reported)</td>
</tr>
<tr>
<td>Kennedy et al, 2007</td>
<td>31; 16</td>
<td>20.5</td>
<td>Venlafaxine (75-225); cognitive behavioral therapy (16)</td>
<td>64 v 41 (P=not reported)</td>
<td>57 v 29 (P=not reported)</td>
<td>−12.9 v −10.8 (P=not reported)</td>
<td>High**</td>
</tr>
<tr>
<td>Lam et al, 2013</td>
<td>105; 12</td>
<td>20.5</td>
<td>Escitalopram (10-20); cognitive behavioral therapy (via telephone) (8) + escitalopram (10-20)</td>
<td>61 v 63 (P=0.86)</td>
<td>53 v 56†† (P=0.74)</td>
<td>Montgomery-Åsberg Depression Rating Scale: −14.3 v −15.7 (P=0.60)</td>
<td>Low</td>
</tr>
<tr>
<td>McGrath et al, 2013</td>
<td>82; 12</td>
<td>18.8</td>
<td>Escitalopram (10-20); cognitive behavioral therapy (16)</td>
<td>60 v 57 (P=not reported)</td>
<td>28 v 29 (P=not reported)</td>
<td>Not reported</td>
<td>High††</td>
</tr>
<tr>
<td>Mynors-Wallis et al, 2000</td>
<td>151; 52</td>
<td>20.3</td>
<td>Fluvoxamine (100-150) or paroxetine (10-40); problem solving therapy (provided by general practitioner) (6); problem solving therapy (provided by nurse) (6); problem solving therapy (provided by nurse) (6) + fluvoxamine (100-150) or paroxetine (10-40)</td>
<td>At 12 weeks: 78 v 64 v 69 v 74 (P=not reported)</td>
<td>At 12 weeks: 67 v 51 v 54 v 6 (P=not reported)</td>
<td>−14.0 v −12.0 v −11.8 v −12.3 (P&gt;0.05)</td>
<td>Medium</td>
</tr>
<tr>
<td>Segal et al, 2006</td>
<td>301; 24 treatment, 96 follow-up</td>
<td>19.5</td>
<td>Sertraline (50-200), paroxetine (20-50), or venlafaxine (75-225); cognitive behavioral therapy (20)</td>
<td>At 24 weeks: 80 v 72 (P=not reported)</td>
<td>At 24 weeks: 71 v 61 (P=not reported)</td>
<td>Not reported</td>
<td>High***</td>
</tr>
<tr>
<td>Shamsaei et al, 2008</td>
<td>120; 8</td>
<td>18.8</td>
<td>Citalopram (20); cognitive therapy (8), citalopram (20) + cognitive therapy (8)</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>High***</td>
</tr>
<tr>
<td>Miranda et al, 2003</td>
<td>178; 4††</td>
<td>16.9</td>
<td>Paroxetine (10-50); cognitive behavioral therapy (8)</td>
<td>Not reported</td>
<td>Not reported</td>
<td>−5.0 v −2.1 (P=0.17)</td>
<td></td>
</tr>
</tbody>
</table>

HRSD=Hamilton Rating Scale for Depression.
*Total number of randomized participants in relevant arms of trial.
†Response (≥50% decrease in depressive severity) and remission (as defined by authors of individual trials) were measured using HRSD unless indicated otherwise.
‡Non-responders were switched to and/or augmented with another drug at 8 weeks.
§For dropouts, only data gathered before attrition were used in continuous outcome models.
¶Continuous data were provided only stratified by depression severity.
**High attrition; completers analysis; difference in baseline age between groups.
††Response was defined as ≥50% decrease in MDRS; remission was defined as MDRS<12.
†††High attrition; completers analysis; no baseline data for part of population.
§§Definition of response was not reported.
¶¶Very high attrition; completers analysis; unclear randomization method.
***Several important aspects of study design and analysis not reported.
†††Although patients received second generation antidepressant for 8 weeks, only 6 week time point was reported.
Table 3 | Strength of evidence and summary of findings

<table>
<thead>
<tr>
<th>Comparison and outcome of interest</th>
<th>Strength of evidence</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Second generation antidepressant versus cognitive behavioral therapy monotherapy comparisons</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remission</td>
<td>Low</td>
<td>Results from direct comparisons in three trials indicate that no differences in remission exist between second generation antidepressants and cognitive behavioral therapy monotherapy (risk ratio 0.98, 95% CI 0.73 to 1.32)</td>
</tr>
<tr>
<td>Response</td>
<td>Moderate</td>
<td>Results from direct comparisons in five trials indicate that no substantial differences in response exist between second generation antidepressants and cognitive behavioral therapy monotherapy (risk ratio 0.91, 0.77 to 1.07)</td>
</tr>
<tr>
<td>Functional capacity</td>
<td>Low</td>
<td>Results from one trial indicate that no substantial differences in functional capacity exist between second generation antidepressants and cognitive behavioral therapy monotherapy</td>
</tr>
<tr>
<td>Overall discontinuation of adverse events</td>
<td>Insufficient</td>
<td>On the basis of one trial with few events, the evidence is insufficient to draw conclusions</td>
</tr>
<tr>
<td>Overall discontinuation of treatment</td>
<td>Moderate</td>
<td>Results from direct comparisons in four trials indicate that no significant differences exist in overall discontinuation between patients treated with second generation antidepressants and those treated with cognitive behavioral therapy (risk ratio 1.00, 0.55 to 1.81)</td>
</tr>
<tr>
<td>Discontinuation of treatment because of adverse events</td>
<td>Low</td>
<td>Results from direct comparisons in three trials indicate that patients treated with second generation antidepressants have a numerically but not statistically significant higher rate of discontinuation because of adverse events than those treated with cognitive behavioral therapy (risk ratio 2.54, 0.39 to 16.47)</td>
</tr>
</tbody>
</table>

**Second generation antidepressant versus combination of second generation antidepressant and cognitive behavioral therapy**

| Remission                         | Low                  | Results from direct comparisons in two trials indicate that no substantial differences in remission exist between second generation antidepressants and second generation antidepressants combined with cognitive behavioral therapy (risk ratio 1.06, 0.82 to 1.38) |
| Response                          | Low                  | Results from direct comparisons in two trials indicate that no substantial differences in response exist between second generation antidepressants and second generation antidepressants combined with cognitive behavioral therapy (risk ratio 1.03, 0.85 to 1.26) |
| Functional capacity               | Low                  | Results from one trial indicate that the combination of second generation antidepressant with cognitive behavioral therapy results in statistically significantly greater improvement on 3/4 work functioning measures than second generation antidepressant alone |
| Overall discontinuation of treatment | Low                  | Results from direct comparisons in two head-to-head trials indicate that no significant differences exist in overall discontinuation between patients treated with second generation antidepressants and those treated with cognitive behavioral therapy (risk ratio 0.77, 0.37 to 1.60) |
| Discontinuation of treatment because of adverse events | Low                  | Results from direct comparisons in two head-to-head trials indicate that no significant differences exist in discontinuation because of adverse events between patients treated with second generation antidepressants and those treated with cognitive behavioral therapy (risk ratio 2.93, 0.72 to 11.91) |

**Fig 2 | Second generation antidepressants (SGA) versus cognitive behavioral therapy (CBT): remission**

**Fig 3 | Second generation antidepressants (SGA) versus cognitive behavioral therapy (CBT): response**

Levels meeting criteria for major depressive disorder; the third defined relapse as either a 17-item Hamilton Rating Scale for Depression score of 14 or greater or a psychiatric status rating of 5 or greater during the first year of follow-up. During the follow-up period of that trial, patients who had initially received cognitive therapy did not receive any treatment, and patients who had received second generation antidepressant were randomized to continue second generation antidepressant or switched to a placebo pill.

In one trial at medium risk of bias, 10.6% of patients treated with second generation antidepressant relapsed within six months, compared with 2.1% and 6.1% of patients treated with rational emotive therapy and cognitive therapy, respectively (statistical significance not reported). In the other trial at medium risk of bias, the rates of relapse within the first year of follow-up were 39% for previous cognitive therapy, 53% for patients who were in the second generation antidepressant arm and continued to receive it during follow-up, and 59% for patients who received second generation antidepressants during the acute phase but were switched to placebo during follow-up. Previous cognitive therapy was significantly different from previous second generation antidepressant switched to placebo (P=0.02). In the trial rated as at high risk of bias, 47% of patients treated with a second generation antidepressant who achieved remission and 39% of those treated with cognitive behavioral therapies who achieved remission relapsed within 18 months (P=0.40).

Finally, one trial at medium risk of bias reported recurrence during the second year of follow-up, defined as either a 17-item Hamilton Rating Scale for Depression...
score of 16 or greater or a psychiatric status rating of 5 or greater among those who did not relapse during year 1 of follow-up. The rates of recurrence during year 2 were 24% for previous cognitive therapy and 52% for patients who were taking second generation antidepressants during the acute phase (P=0.06). Owing largely to small numbers of patients in each group (17 in each group), the difference was not statistically significant. The single trial (also at medium risk of bias) that reported measures of functional capacity used the Social Adjustment Scale; second generation antidepressant and problem solving therapy did not differ at end of treatment or at 40 week off-treatment follow-up (P=0.05 at both times).

With regard to adverse events, reporting was generally poor, particularly for serious adverse events and specific adverse events. As a result, we analyzed rates of discontinuation as proxies for adverse events. Overall discontinuation from the four studies at medium risk of bias did not differ significantly between second generation antidepressants and cognitive behavioral therapies (risk ratio 1.00, 0.55 to 1.81; P=0.47; moderate strength of evidence). Adding three studies at high risk of bias did not change the result (risk ratio 0.92, 0.69 to 1.23). More patients treated with a second generation antidepressant than receiving cognitive behavioral therapy withdrew from studies owing to adverse events (risk ratio 2.54, 0.39 to 16.47; three studies; P=0.62%), but the difference was not statistically significant (low strength of evidence). Again, including a trial at high risk of bias did not affect the results (risk ratio 2.97, 0.69 to 12.81). Finally, second generation antidepressants and cognitive behavioral therapies did not differ significantly in terms of dropouts attributed to lack of efficacy in the main analysis (risk ratio 0.36, 0.06 to 2.21; three studies; P=0.51%).

Second generation antidepressant versus cognitive behavioral therapy: combination comparisons

The three trials that compared second generation antidepressant monotherapy with a combination of second generation antidepressant and cognitive behavioral therapy reported no statistically significant between group differences in rates of either remission or response (low strength of evidence). All reported change in depression scale score between baseline and endpoint; one reported a significant between group difference—namely, a smaller decrease in scores on the Montgomery-Åsberg Depression Rating Scale for patients taking second generation antidepressant alone than for patients treated with second generation antidepressant plus cognitive therapy. That trial, however, was rated as at high risk of bias, whereas the other two were rated as at low and medium risk of bias.

The trial that compared second generation antidepressant alone with second generation antidepressant plus telephone cognitive behavioral therapy measured several work related outcomes. Patients receiving the combination of second generation antidepressant and telephone cognitive behavioral therapy reported greater improvement on three of four work functioning measures. The authors found no between group differences in reduction of hours of work missed, although both groups reported a decrease at the end of treatment. In the trial that compared second generation antidepressant alone with the combination of second generation antidepressant and problem solving therapy, groups did not differ in the Social Adjustment Scale at end of treatment or at 40 week off-treatment follow-up.

Two of the three trials reported adverse events. In the trial rated as at low risk of bias, more patients withdrew for any reason from the combination arm than from the second generation antidepressant alone arm (23% v 13%; significance not reported). However, slightly more patients withdrew owing to adverse events from the second generation antidepressant alone arm (6%) compared with the combination arm (4%). In the other trial, rated as at medium risk of bias, discontinuation rates were similar between the second generation antidepressant alone and combination arms (17% in each arm). Eleven per cent and 6% of patients in the combination and second generation antidepressant arms, respectively, withdrew because of adverse events. No patients in either arm withdrew because of lack of treatment efficacy. The low number events in each of these outcomes results in a low strength of evidence rating.

Discussion

For second generation antidepressants compared with cognitive behavioral therapies, the available evidence based on 11 randomized controlled trials with 1511 patients suggests no difference in treatment effects of second generation antidepressants and cognitive behavioral therapies, either alone or in combination, although our conclusions are tempered by small numbers and mostly low strength of evidence. Relative risks of remission and response were nearly identical for monotherapy comparisons (0.98 and 0.91, respectively) and for second generation antidepressant alone versus combination (1.06 and 1.03, respectively). Adverse event outcomes were also clinically and statistically similar for all comparisons.

Comparison with other studies and guidelines

Our findings are relatively consistent with similar meta-analyses by Cuipers and colleagues that compared second generation antidepressants with...
cognitive behavioral therapy. In addition to containing several more recent studies, our analyses have some key methodological differences that make them more relevant for the primary care population. Cuijpers and colleagues did meta-analyses of second generation antidepressants compared with any psychotherapy and of cognitive behavioral therapy compared with any drug, but they did not report results from a specific comparison between second generation antidepressant and cognitive behavioral therapy for adults with major depressive disorder. They found that only selective serotonin reuptake inhibitors, rather than second generation antidepressants as a class, were more effective than any type of psychotherapy in treating patients with major depressive disorder; however, the effect was small and potentially clinically insignificant. Furthermore, they did not require the use of evidence based psychotherapy (for example, non-directive supportive counseling was eligible for their analyses), they did not limit studies to those in which patients had not already failed a previous antidepressant treatment (who would be more likely to be seen in primary care). Finally, their analyses did not report on comparative harms, which we have done in this report.

Spielmans and colleagues found that bona fide cognitive behavioral therapy (based on their included studies’ descriptions of therapist training, therapist-client relationship, and therapy components) resulted in better outcomes that second generation antidepressant, but the effect sizes were small and heterogeneity was high. Although we considered treatment fidelity in our risk of bias assessment, we did not attempt to determine whether the cognitive behavioral therapy offered in the included trials was “bona fide.” Because primary care clinicians are unlikely to have the information necessary to determine whether the cognitive behavioral therapy to which they refer patients is bona fide, our results may be more relevant to primary care providers. Our results are also consistent with the recommendations of the American Psychiatric Association, the US Department of Veterans Affairs/Department of Defense, and the UK National Institute for Health and Care Excellence. Those groups consider both drugs and psychotherapy to be appropriate individual initial treatments for patients with mild to moderate major depressive disorder. Furthermore, they state that drugs plus psychotherapy may be a useful initial treatment for patients with a current episode of moderate to severe major depressive disorder and for those with major depressive disorder and coexisting conditions.

Limitations
This review, and the evidence that informed it, does have limitations. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with cognitive behavioral therapy (alone or in combination with a second generation antidepressant). We did not attempt to review the literature on interventions for major depressive disorder in children or for patients with subthreshold depression, dysthymia, or perinatal depression. The included trials enrolled mostly patients with moderate to severe major depressive disorder; therefore, results may not be applicable to patients with milder major depressive disorder. Most trials excluded patients with medical comorbidities or suicidal ideation; few trials included elderly patients. We found insufficient evidence to confirm or refute whether treatments are more or less efficacious for various subgroups (patients characterized by sex, race, or ethnicity or those with coexisting psychiatric conditions).

Many of the included trials, even those rated as at medium risk of bias, had methodological shortcomings that may limit confidence in some of our findings. Several studies reported very high attrition, although rates were usually similar between treatment groups. Our “worst case” assumption of withdrawals as failures to respond or remit should alleviate some of that concern. Most of the included trials provided data only for acute phase treatment; information to help providers to manage ongoing depression or prevent relapse and recurrence is lacking.

Although studies of psychotherapy contain some inherent heterogeneity of the content and delivery, the included trials used treatment manuals with prescribed goals and techniques to minimize variability between therapists. The type, training, and experience of the clinicians who render these various interventions were also quite diverse. Unlike the case with second generation antidepressants, which are broadly equivalent and have standardized dosing, the cumulative effect of the various sources of heterogeneity within and across psychological interventions may limit the applicability of our findings. Clinician type, training, experience, and degree of treatment fidelity are likely to be even less consistent in routine clinical practice than in the trials in this review. Along with availability of psychotherapists, these are important factors for clinicians to consider when recommending psychological treatment and interventions.

Finally, comparative effectiveness at a group level did not detect a difference between second generation antidepressants and cognitive behavioral therapies, but how best to tailor this information to an individual patient is still not clear, especially given the low strength of evidence for most of the included outcomes. Preliminary evidence suggests that biomarkers may have a role in predicting response to cognitive behavioral therapy compared with second generation antidepressants, but these findings have yet to be replicated or implemented in clinical practice. Analyses of individual patient level data are best suited to answer that question and should be done in the future. Although we searched for unpublished literature, publication bias and selective outcome reporting may still be potential limiting factors. Finally, because we did not compare active treatment with placebo or no treatment, we cannot rule out the possibility that cognitive behavioral therapy and second generation antidepressants may be...
similarly ineffective. However, because evidence of benefit from both treatments exists, a provider would be unlikely recommend no treatment instead.

Conclusions and policy implications
In clinical decision making, providers should consider not only the efficacy of second generation antidepressants and cognitive behavioral therapy interventions but also patients’ preferences about potential adverse events, the costs and availability of each treatment, and expected treatment effects. Currently, the biggest barrier to offering psychotherapy either alone or in combination with drugs may be how well patients can gain access to such mental healthcare clinicians. Given that the benefits of second generation antidepressants and cognitive behavioral therapy do not seem to differ significantly in treating major depressive disorder and that primary care patients may have personal preferences for one first line treatment over the other, both treatments should be made accessible, either alone or in combination, to primary care patients with major depressive disorder.4

Having access to psychotherapeutic interventions in the primary care setting might improve treatment outcomes for patients with major depressive disorder. It has the potential to improve use of psychiatric consultations and therapy and to enhance coordination of care between primary care clinicians and mental health professionals. It may also have additional downstream effects of reducing the stigma associated with mental illness in general, empowering patients to tackle the symptoms and problems associated not only with depression but also with other mental health related concerns and encouraging them to seek and maintain treatment more quickly at an earlier stage of their illness.

We thank Meera Viswanathan and Loraine Monroe, both from RTI International, for dedicated support and Irma Klerings from Danube University, Krems, for literature searches.

Contributors: HRA reviewed studies for inclusion and exclusion; entered, cleaned, and analyzed the data; did statistical analyses; and drafted and revised the paper. GG oversaw the design and conduct of the full report from which this manuscript was devised, reviewed included studies, analyzed data, and revised the draft paper. BNG, CF, GNA, LCM, ECS, EB, LJL, SG, CB, and CBP participated fully in the report from which this manuscript was devised, reviewed included studies, entered and cleaned data, and revised the draft paper. BNG, LCM, and CB also did data analyses. KNL contributed to the full report, from which this project was based and revised the draft paper. HRA is the guarantor.

Funding: This project was funded under contract 290-2012-00008i from the Agency for Healthcare Research and Quality by the RTI-UNC Evidence-based Practice Center. The authors of this manuscript are responsible for its content. Statements in this manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services.

Competing interests: The authors have completed the ICME uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization other than the funding agency listed above for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not needed for this project.

Data sharing: Detailed methods and additional information are available in the full report, available at http://effectivehealthcare.ahrq.gov/.

Transparency: The lead author (the manuscript’s guarantor) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


49. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for management of major depressive disorder (major depressive disorder). Department of Veterans Affairs, Department of Defense, 2009.